Stock comparison
Apellis Pharmaceuticals
APLS$5.25BHealthcare Market cap, Sector
Halozyme Therapeutics
HALO$8.1BHealthcare Market cap, Sector
Overall winner
Tie
APLS 34 HALO
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
APLS3wins
4winsHALO
58D
B79
79B
B83
71B
C65
81B
D53
63C
F40
67C
B80
65C
B84
Side-by-side metrics
| Metric | APLS | HALO |
|---|---|---|
| Market cap | $5.25B | $8.1B Winner |
| P/E (TTM) | 38.8x | 24.0x Winner |
| EV/EBIT | 96.0x | 10.2x Winner |
| ROIC (TTM) |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
APLS leads on
- Revenue CAGR 5y97.06%vs 33.23%+66%
- Gross margin90.12%vs 81.24%+10%
HALO leads on
- EV/EBIT10.2xvs 96.0x+89%
- Net margin23.13%vs 12.06%+48%
More like HALO
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.